361 Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

361 Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-47,056	Closed	-$3.9M	–	165
2016 Q4	$3.9M	Buy	+47,056	New	+$4.05M	0.93%	46

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

361 Capital's BMRN Position: Q1 2017 in Review

361 Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2017, closing a stake of 47,056 shares — an estimated $3.9M sold.

361 Capital first reported a position in BMRN in Q4 2016 and held it in 1 quarter. The position peaked at $3.9M in Q4 2016. 417 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

361 Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
361 Capital sold 47,056 BioMarin Pharmaceuticals shares in Q1 2017, an estimated $3.9M.
361 Capital first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 1 quarter.
361 Capital's BioMarin Pharmaceuticals position peaked at $3.9M in Q4 2016.
417 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on 361 Capital's 13F filing for Q1 2017, filed 2 May 2017.